Sandoz Group Ltd

Latest Results (26.10.2025):

Sandoz Group Ltd reported strong financial results for the first half of 2025, demonstrating robust growth across its generics and biosimilars segments. The company achieved a 4% increase in net sales at constant currencies and an 18% rise in core EBITDA, underscoring its strategic focus and market performance during this period.

Net Sales Growth

Sandoz Group Ltd’s net sales for H1 2025 reached USD 5,232 million, marking a 4% increase at constant currencies and a 6% growth on a comparable growth rate (CGR) basis. This growth was primarily driven by a 12% rise in biosimilars and a 1% increase in generics.

Strong Biosimilars Performance

The biosimilars segment saw a significant uptick, with sales growing by 12% at constant currencies and 17% on a CGR basis, contributing 29% to total net sales. This performance highlights Sandoz’s continued investment and strategic initiatives in the biosimilars market.

Generics Segment Stability

The generics division maintained steady growth, with net sales increasing by 1% at constant currencies and 2% on a CGR basis. Generics accounted for 71% of total net sales, reflecting consistent performance despite a challenging market environment.

Enhanced Profitability

Core EBITDA rose by 18% to USD 1,046 million, with the core EBITDA margin improving to 20.0%. This enhancement was driven by operational efficiencies and a favorable sales mix.

Increased Earnings and Cash Flow

Core diluted earnings per share grew by 30% to USD 1.46, and management free cash flow surged to USD 503 million, compared to USD 237 million in H1 2024. These improvements highlight Sandoz’s strong financial health and effective capital management.

Full-Year 2025 Guidance

Sandoz Group Ltd confirmed its full-year 2025 guidance, expecting mid-single-digit net sales growth at constant currencies and a core EBITDA margin of around 21%. The company anticipates continued strength in the second half of the year, particularly in North America.